Completed PHASE2 INTERVENTIONAL 1-arm NCT00516412

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Everolimus (RAD001) for the Treatment of Patients With Relapsed or Therapy Resistant Mantle Cell Lymphoma

Sponsor: Swiss Cancer Institute

Conditions Lymphoma

Interventions everolimus molecular response by PCR

Updated 7 times since 2017 Last updated: Sep 28, 2015 Started: Aug 31, 2007 Primary completion: Jan 31, 2010 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lymphoma, this trial is completed. The trial is conducted by Swiss Cancer Institute and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Aug 2025 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Aug 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss Cancer Institute

Data source: Swiss Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Baden, Switzerland , Basel, Switzerland , Bellinzona, Switzerland , Bern, Switzerland , Bologna, Italy , Chur, Switzerland , Grenoble, France , Lausanne, Switzerland , Milan, Italy and 8 more locations